Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
341.3 INR | +1.58% | +10.19% | +36.67% |
Jun. 07 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
May. 31 | Biocon Limited Receives Show Cause Notice from the Assistant Commissioner of Customs, Chennai | CI |
Sales 2024 | 148B 1.77B | Sales 2025 * | 161B 1.93B | Capitalization | 401B 4.8B |
---|---|---|---|---|---|
Net income 2024 | 10.22B 122M | Net income 2025 * | 8.97B 107M | EV / Sales 2024 | 2.14 x |
Net Debt 2024 * | 139B 1.67B | Net Debt 2025 * | 131B 1.57B | EV / Sales 2025 * | 3.29 x |
P/E ratio 2024 |
30.9
x | P/E ratio 2025 * |
45.9
x | Employees | 16,545 |
Yield 2024 * |
0.43% | Yield 2025 * |
0.29% | Free-Float | 37.18% |
Latest transcript on Biocon Limited
1 day | +1.00% | ||
1 week | +9.59% | ||
Current month | +9.73% | ||
1 month | +11.63% | ||
3 months | +21.54% | ||
6 months | +41.37% | ||
Current year | +35.93% |
Managers | Title | Age | Since |
---|---|---|---|
Siddharth Mittal
CEO | Chief Executive Officer | 46 | 13-04-30 |
Peter Bains
CEO | Chief Executive Officer | 65 | 22-12-11 |
Chairman | 71 | 78-11-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 71 | 78-11-28 | |
Director/Board Member | 69 | 99-12-31 | |
Director/Board Member | 60 | 18-07-26 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.17% | 6 M€ | +6.07% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 341.3 | +1.58% | 6 257 857 |
24-06-07 | 336 | +0.98% | 14,591,280 |
24-06-06 | 332.8 | +9.01% | 17,874,580 |
24-06-05 | 305.2 | +4.93% | 8,516,880 |
24-06-04 | 290.9 | -6.06% | 17,873,000 |
Delayed Quote NSE India S.E., June 10, 2024 at 02:19 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+35.93% | 4.8B | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- BIOCON Stock